Background Glioblastoma patients administered standard therapies, comprising maximal
surgical resection, radiation therapy with concomitant and adjuvant temozolomide, have a …

Background The aim of this study was to determine correlations between progression-free
survival (PFS) and the objective response rate (ORR) with overall survival (OS) in …

Background Glioblastoma is the most frequent primary malignant brain tumor. In daily
practice and at whole country level, oncological care management for glioblastoma patients …

Background Prospective follow-up studies of large cohorts of patients with glioblastoma
(GBM) are needed to assess the effectiveness of conventional treatments in clinical practice …

Background Although implementation of temozolomide (TMZ) as a part of primary therapy
for glioblastoma multiforme (GBM) has resulted in improved patient survival, the disease is …

Background Glioblastoma is the most common and most aggressive primary brain tumor in
adults. Despite multimodal treatment, the median survival time is 15–16 months and 5-year …

Background Historical controls continue to be used in early-phase brain tumor trials. We aim
to show that historical changes in survival trends for glioblastoma (GBM) call into question …

Background A randomised trial published by the European Organisation for Research and
Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical …

Objectives To address in a retrospective and population‐based study prognostic factors for
survival time after diagnosis and surgery for glioblastoma multiforme (GBM). Material and …

Simple Summary Glioblastoma is the most common tumour that originates in the brain in
adults. Most of the published data on glioblastoma are from patients in clinical trials who …